Journal article
The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
- Abstract:
-
Diabetes is a common cause of chronic kidney disease (CKD), but in aggregate, non-diabetic diseases account for a higher proportion of cases of CKD than diabetes in many parts of the world. Inhibition of the renin–angiotensin system reduces the risk of kidney disease progression and treatments that lower blood pressure (BP) or low-density lipoprotein cholesterol reduce cardiovascular (CV) risk in this population. Nevertheless, despite such interventions, considerable risks for kidney and CV c...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Authors
Funding
Bibliographic Details
- Publisher:
- Oxford University Press Publisher's website
- Journal:
- Clinical Kidney Journal Journal website
- Volume:
- 11
- Issue:
- 6
- Pages:
- 749–761
- Publication date:
- 2018-10-25
- Acceptance date:
- 2018-08-24
- DOI:
- EISSN:
-
2048-8513
- ISSN:
-
2048-8505
- Source identifiers:
-
923310
Item Description
- Pubs id:
-
pubs:923310
- UUID:
-
uuid:6921189b-3226-4398-848d-a679f8d6e0da
- Local pid:
- pubs:923310
- Deposit date:
- 2018-10-03
Terms of use
- Copyright holder:
- Herrington, et al
- Copyright date:
- 2018
- Notes:
-
© The Author(s) 2018. Published by Oxford University Press on behalf of ERA-EDTA.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record